PuraMed BioScience® Announces Science Behind LipiGesic® M Migraine Treatment
SCHOFIELD, Wis., June 21, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB:PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced the science behind LipiGesic® M, its homeopathic, over-the-counter migraine medication.
PuraMed BioScience began the formulation process using the laboratory method and in-vitro analysis. By simulating an inflammatory response similar to the inflammation experienced by people with migraine, PMBS was able to test the effectiveness of LipiGesic M's active ingredients. The resulting in-vitro analysis showed a near total inhibition of both nitrous oxide synthesis and nuclear factor kappa beta.
These were key findings since nitrous oxide and nuclear factor kappa beta have been shown to play significant roles in the development of inflammation and the development of migraine pain and associated symptoms.
"Based on the evidence, I believe that the inhibition of nitrous oxide production is a key mechanism of action for LipiGesic M," said Russell Mitchell, CEO of PuraMed BioScience. "This unique approach is proving to be a breakthrough in the treatment of acute migraine. Recently, renowned headache experts have declared LipiGesic M 'an excellent first-line therapy' in the treatment of acute migraine. To further our product development, we plan to conduct additional testing on other inflammatory markers that may be involved in the onset of migraine and other inflammatory diseases."
PuraMed BioScience developed a sublingual delivery method to deliver LipiGesic M's low-dose actives of ginger and feverfew most effectively. NF grade olive oil was chosen because it:
- acts as the proper base for lipid-soluble actives;
- contains oleic acid, which is a proven permeation enhancer that increases blood flow at the site of application;
- contains oleocanthal, which has similar activity to ibuprofen.
"Sublingual delivery provides for more efficient delivery and improves efficacy by avoiding the destruction from the 'first-pass effect,'" said Mitchell. "Sublingual delivery provides a direct path into the bloodstream allowing for much faster relief versus pills which can take up to an hour to enter the bloodstream after passing through the stomach and liver. It also allows lower-levels of active ingredients, which typically reduce or eliminate the occurrence of side effects."
LipiGesic M is packaged in pre-measured unit dose sachets. For more information, or to purchase the product online, please visit www.lipigesic.com.
About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic M, PuraMed BioScience plans to launch LipiGesic H for tension-type headaches and LipiGesic PM, which provides a remedy for insomnia and other sleep disorders. www.puramedbioscience.com
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties that may cause actual results and future achievements to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
South Street Media, Inc
Phone: (917) 937-8968
SOURCE PuraMed BioScience, Inc.